Zai Lab Ltd. ADR (ZLAB): Price and Financial Metrics


Zai Lab Ltd. ADR (ZLAB): $33.58

-0.42 (-1.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ZLAB to Watchlist
Sign Up

Industry: China


Ranked

of

in industry

ZLAB POWR Grades

  • ZLAB scores best on the Growth dimension, with a Growth rank ahead of 72.31% of US stocks.
  • ZLAB's strongest trending metric is Sentiment; it's been moving down over the last 177 days.
  • ZLAB's current lowest rank is in the Momentum metric (where it is better than 4.49% of US stocks).

ZLAB Stock Summary

  • With a one year PEG ratio of 0.54, ZAI LAB LTD is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.96% of US stocks.
  • The ratio of debt to operating expenses for ZAI LAB LTD is higher than it is for about only 8% of US stocks.
  • ZLAB's price/sales ratio is 16.8; that's higher than the P/S ratio of 93.56% of US stocks.
  • Stocks that are quantitatively similar to ZLAB, based on their financial statements, market capitalization, and price volatility, are TDUP, APM, HCWB, TVTX, and FNCH.
  • Visit ZLAB's SEC page to see the company's official filings. To visit the company's web site, go to www.zailaboratory.com.

ZLAB Valuation Summary

  • ZLAB's price/earnings ratio is -6; this is 125.64% lower than that of the median Healthcare stock.
  • Over the past 63 months, ZLAB's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ZLAB.

Stock Date P/S P/B P/E EV/EBIT
ZLAB 2022-12-02 18.2 3.2 -6.0 -4.2
ZLAB 2022-12-01 18.0 3.2 -6.0 -4.1
ZLAB 2022-11-30 19.2 3.4 -6.4 -4.5
ZLAB 2022-11-29 16.8 3.0 -5.6 -3.7
ZLAB 2022-11-28 15.5 2.7 -5.1 -3.3
ZLAB 2022-11-25 15.8 2.8 -5.2 -3.4

ZLAB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZLAB has a Quality Grade of C, ranking ahead of 42.52% of graded US stocks.
  • ZLAB's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ZLAB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.653 -5.744
2020-12-31 0.059 0.658 -0.531
2020-06-30 0.058 0.727 -0.851
2020-06-30 0.058 0.727 -0.851
2019-12-31 0.040 0.711 -0.887
2019-12-31 0.040 0.711 -0.889

ZLAB Stock Price Chart Interactive Chart >

Price chart for ZLAB

ZLAB Price/Volume Stats

Current price $33.58 52-week high $73.85
Prev. close $34.00 52-week low $20.98
Day low $31.73 Volume 72,512
Day high $33.91 Avg. volume 679,280
50-day MA $31.61 Dividend yield N/A
200-day MA $37.68 Market Cap 3.29B

Zai Lab Ltd. ADR (ZLAB) Company Bio


Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases and neurological disorders to patients in China and around the world. Our longer-term goal is to leverage our China-based competencies and resources to enable and impact human health worldwide. (Source:ZaiLaborator)


ZLAB Latest News Stream


Event/Time News Detail
Loading, please wait...

ZLAB Latest Social Stream


Loading social stream, please wait...

View Full ZLAB Social Stream

Latest ZLAB News From Around the Web

Below are the latest news stories about ZAI LAB LTD that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.

Zai Lab Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Zai Lab ( NASDAQ:ZLAB ) Third Quarter 2022 Results Key Financial Results Revenue: US$57.5m (up 34% from 3Q 2021). Net...

Yahoo | November 12, 2022

Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates

Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q; continued revenue growth led by ZEJULA Regional strategic collaboration for TIVDAK® (tisotumab vedotin) strengthens Zai Lab’s leadership in developing and providing access to medicine to treat women’s cancer in ChinaStrong balance sheet with a cash position of $1.12 billionCompany to host a conference call and webcast on November 10, 2022, at 8:00 a.m. ET SHANGHAI and CAMBRIDGE, Ma

Yahoo | November 9, 2022

Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting

Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumorsSHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present new data from its internal immuno-oncology pipeline at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Me

Yahoo | November 8, 2022

Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer

SHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Dr. Peter Huang as its Chief Scientific Officer (CSO), effective immediately. Dr. Huang brings an extensive scientific background and strong leadership and research and development experience, including over 16 years working within the biopharmaceutical industry, to Zai Lab

Yahoo | November 8, 2022

The Zacks Analyst Blog Highlights Zai Lab, Li Auto, Dingdong (Cayman), Autohome and JD.com

Zai Lab, Li Auto, Dingdong (Cayman), Autohome and JD.com are part of the Zacks top Analyst Blog.

Yahoo | November 4, 2022

Read More 'ZLAB' Stories Here

ZLAB Price Returns

1-mo 4.84%
3-mo -22.50%
6-mo 26.19%
1-year -52.36%
3-year -18.65%
5-year 31.74%
YTD -46.57%
2021 -53.56%
2020 225.41%
2019 79.11%
2018 9.37%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6047 seconds.